常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-44.70/-1.15
|
|
企業價值
12.18M
|
| 資產負債 |
|
每股賬面淨值
-3.24
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
42.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 02:43 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea. |

6.27 
